CRISPR Gene Editing: From Lab Breakthrough to Clinical Applications

In December 2023, Two People Were Cured of Sickle Cell Disease Using CRISPR

The FDA approved Casgevy (exa-cel) on December 8, 2023 — the first CRISPR-based medicine licensed for human use. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, it offered patients with sickle cell disease and transfusion-dependent beta-thalassemia a functional cure: a single treatment that edits a patient's own stem cells to reactivate fetal hemoglobin production, bypassing the defective adult hemoglobin gene. The clinical trial results showed 29 of 29 treated sickle cell patients remained free of severe vaso-occlusive crises for at least 12 months. A technology first demonstrated in bacteria in the 1980s had, within a decade of its laboratory refinement, cured a genetic disease that has affected humans since ancient Egypt.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) refers to sequences in prokaryotic DNA that form part of a bacterial immune system. The CRISPR-Cas9 system — first described as a programmable gene editing tool in a landmark 2012 Science paper by Jennifer Doudna and Emmanuelle Charpentier — repurposes this bacterial mechanism to make precise cuts in any DNA sequence, enabling deletion, correction, or insertion of genetic material.

How CRISPR-Cas9 Works

The CRISPR-Cas9 system consists of two components:

• Cas9 protein: A nuclease (molecular scissors) that cuts double-stranded DNA. Derived from Streptococcus pyogenes for most current applications.
• Guide RNA (gRNA): A short RNA sequence (~20 nucleotides) designed to match the target DNA sequence. The gRNA directs Cas9 to the precise genomic location to be cut.

When Cas9 creates a double-strand break in DNA, the cell's natural repair machinery activates. Two repair pathways exist:

• Non-homologous end joining (NHEJ): Error-prone repair that typically introduces small insertions or deletions (indels), disrupting or "knocking out" the target gene.
• Homology-directed repair (HDR): If a DNA template is provided alongside the CRISPR machinery, the cell can incorporate the template sequence — enabling precise corrections. HDR efficiency in non-dividing cells remains a major research challenge.

Clinical Applications: From Bench to Bedside

Delivery: The Remaining Bottleneck

Getting CRISPR components into the right cells in the body is as important as the editing itself. Three main delivery strategies exist:

• Ex vivo editing: Remove cells from the patient, edit them in the lab, and reinfuse. Used for Casgevy (blood stem cells). Highly controlled but applicable only to blood and immune cell diseases.
• Lipid nanoparticles (LNPs): The same delivery vehicle used in mRNA COVID-19 vaccines. Effective for liver targeting; Intellia's NTLA-2001 uses LNPs to deliver Cas9 mRNA and gRNA directly to hepatocytes in vivo.
• Adeno-associated viruses (AAVs): Viral delivery for muscle, eye, and CNS applications. Limited packaging capacity is a challenge for the large Cas9 protein; split-Cas9 approaches are being developed to address this.

Base Editing and Prime Editing: Beyond CRISPR-Cas9

Standard CRISPR-Cas9 makes double-strand breaks — an imprecise process associated with off-target cuts and unintended chromosomal rearrangements. Newer tools reduce these risks:

• Base editors (David Liu, Broad Institute, 2016): Convert one DNA base letter into another (C→T or A→G) without cutting both DNA strands. Can correct point mutations responsible for thousands of genetic diseases. Several base editing therapies are in clinical trials.
• Prime editors (David Liu, 2019): Use a modified Cas9 nickase and reverse transcriptase to write new genetic information directly into the genome without double-strand breaks and without requiring a separate DNA template. Capable of all 12 types of point mutation corrections.

He Jiankui and the Ethics of Germline Editing

In November 2018, Chinese researcher He Jiankui announced he had created the world's first gene-edited human babies — twin girls whose embryos had been edited to disable the CCR5 gene, intended to confer HIV resistance. The announcement was immediately condemned by the global scientific community. He Jiankui was subsequently tried in a Chinese court and sentenced to three years in prison for conducting illegal medical practice. The case exposed the absence of a binding international governance framework for human germline editing — modifications that would be heritable. The 2020 International Commission on the Clinical Use of Human Germline Genome Editing concluded that germline editing should not proceed clinically until mechanisms for societal dialogue and governance are established. The 2020 Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier — the same year He Jiankui was released from prison.